ClinicalTrials.gg
RecruitingNCT06927635SECUREUpdated Jul 7, 2026

Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer

A Phase 2 interventional study of Stereotactic Body Radiation Therapy (SBRT) and Systemic therapy in Castrate Resistance Prostate Cancer and OligoProgressive Metastatic Disease, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Prostatic Neoplasms by University Health Network, Toronto — 23 open to participants now, 29 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.

Planned enrollment
30th of 86
75 · median 44
Started
2025
with 4 others
Phase 2
29 of 102
7 open now
Primary completion
2030-06
later than 23 of 28 live
Registered
96th of 102
by date

Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 30th largest by planned enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2025, is one of 29 in phase 2, reaches primary completion later than 23 of the 28 other live ones, and was the 96th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

23 of the 102 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Prostatic Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).

Read the detailed description

The current standard of care for patients with metastatic Oligopressive (OP) Castrate Resistance Prostate Cancer (CRPC) is a change in Systemic Therapy (ST). We propose that Stereotactic Body Radiotherapy (SBRT) to Oligopressive sites, while maintaining patients on their current Systemic Therapy, may allow for biochemical control of disease while maintaining patient Quality of Life and avoiding the toxicities associated with changing Systemic Therapy. We have proposed an initial prospective feasibility study, followed by a larger phase II prospective study to investigate the efficacy of SBRT in Oligopressive Castrate Resistance Prostate Cancer.

03

Conditions studied

  • Castrate Resistance Prostate Cancer
  • OligoProgressive Metastatic Disease

Browse trials for

Keywords

  • systemic therapy
  • stereotactic body radiation therapy (SBRT)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Able to provide
  • Histologic diagnosis of prostate adenocarcinoma
  • Castrate Resistance Prostate Cancer
  • Radiographic evidence of \<10 sites of extra-cranial OP lesions
  • Receiving any line of ST for >3 months
  • All sites of OP disease are amenable to and can be safely treated with SBRT
  • performance status 0-3

Exclusion criteria

Exclusion Criteria:

  • Evidence of spinal cord compression
  • to radiotherapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Arm 1 - Standard of Care

    Participants on Arm 1 - SOC will be treated as per standard of care by their treating Oncologist. In most instances, it is anticipated participants will undergo a change in Systemic Therapy (ST) (including best supportive care). The ST will be at the discretion of the Oncologist and patient, according to best practices for the patient's diagnosis and clinical scenario. Patients can receive palliative radiotherapy for standard indications at any time.

    Radiation: Stereotactic Body Radiation Therapy (SBRT) · Other: Systemic therapy

  • Experimental
    Arm 2 - Experimental

    Participants on Arm 2 - Experimental will receive standard of care SBRT to oligoprogressive sites according to institutional standards while remaining on the systemic treatment prescribed by the treating oncologist.

    Radiation: Stereotactic Body Radiation Therapy (SBRT) · Other: Systemic therapy

Interventions

  • RadiationStereotactic Body Radiation Therapy (SBRT)

    SBRT will be delivered as per institutional standard.

  • OtherSystemic therapy

    Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.

06

What researchers measure

Primary outcomes

  1. Study Feasibility

    Determine the feasibility of enrolling 21 patients patients onto a study randomizing patients to either MDT using SBRT plus remaining on current ST versus SoC (change in Systemic Therapy) by measuring the rate accrual (number of patients per month for 18 months).

    Time frame: Within 18 months of study activation.

  2. Change in Prostate-Specific Antigen (PSA)

    Assess by standard PSA blood testing if the proportion of patients having a \>50% change in PSA compared to baseline (PSA50) is improved with MDT using SBRT plus remaining on current ST versus SoC.

    Time frame: Enrollment to 12 months post-enrollment.

Secondary outcomes

  1. Radiographic Local Control of Oligopressive Lesions

    Radiographic local control of the index OP lesions will be assessed by treating oncologist.

    Time frame: Enrollment to 12 months-post enrollment.

  2. Radiographic Distant Control of Oligopressive Lesions

    Defined by growth of non-Oligoprogressive metastatic sites and/or the development of new sites of metastatic disease, as assessed by treating oncologist.

    Time frame: Enrollment to 12-months post-enrollment.

  3. Progression Free Survival (PFS)

    Defined as the time from randomization to death from any cause, progression of disease, or date of last follow-up, whichever occurs first. PFS will be assessed by the treating oncologist.

    Time frame: Enrollment to 12-months post-enrollment.

  4. Time to next Systemic Therapy

    Defined as the time from when the study intervention has been commenced until commencement of any next systemic anti-cancer therapy (including a change to best supportive care) or date of last follow up, whichever occurs first, which will be assess by the treating oncologist.

    Time frame: Enrollment to 12-months post-enrollment.

  5. Differences in Toxicity

    Toxicity will be assessed to determine whether SBRT compared to SoC results in patient- and/or physician-reported toxicity differences. Toxicity will be collected using CTCAE v5.0

    Time frame: Enrollment to 12-months post-enrollment.

  6. Differences in Quality of Life

    Quality of Life (QoL) will be assessed to determine whether SBRT compared to SoC results in patient- and/or physician-reported QoL differences. QoL will be collected using the EORTC QLQ-C30 questionnaire.

    Time frame: Enrollment to 12-months post-enrollment.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 59 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Apr 15, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06927635
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Jul 8, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jul 7, 2026

Study contacts

Rachel Glicksman, MD
Contact
rachel.glicksman@uhn.ca
416-946-4501 ext. 4961
Rachel Glicksman, MD
principal investigator · Princess Margaret Cancer Centre - University Health Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion